Generation Bio Co logo

Generation Bio CoNASDAQ: GBIO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

12 June 2020

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$147.50 M
-88%vs. 3y high
48%vs. sector
-vs. 3y high
-vs. sector
-59%vs. 3y high
46%vs. sector
-97%vs. 3y high
76%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:03:21 GMT
$2.21+$0.03(+1.38%)

Dividend

No data over the past 3 years
$4.09 M$2.35 M
$4.09 M-$20.43 M

Analysts recommendations

Institutional Ownership

GBIO Latest News

Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress
globenewswire.com22 October 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented data on its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress.

Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research13 May 2024 Sentiment: NEGATIVE

GBIO reported a quarterly loss of $1.12 per share, which was higher than the Zacks Consensus Estimate of a loss of $0.36. This is an increase from the loss of $0.53 per share reported in the same quarter last year.

Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research06 March 2024 Sentiment: NEGATIVE

Generation Bio Co. (GBIO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.55 per share a year ago.

Generation Bio to Present at the 2024 TD Cowen Health Care Conference
GlobeNewsWire27 February 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2024 TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 9:10 a.m. ET in Boston.

Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research10 May 2023 Sentiment: NEGATIVE

Generation Bio Co. (GBIO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.61 per share a year ago.

Generation Bio to Present at the JMP Securities Life Sciences Conference
GlobeNewsWire09 May 2023 Sentiment: POSITIVE

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023 at 1:00 p.m. EST in New York.

What type of business is Generation Bio Co?

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

What sector is Generation Bio Co in?

Generation Bio Co is in the Healthcare sector

What industry is Generation Bio Co in?

Generation Bio Co is in the Biotechnology industry

What country is Generation Bio Co from?

Generation Bio Co is headquartered in United States

When did Generation Bio Co go public?

Generation Bio Co initial public offering (IPO) was on 12 June 2020

What is Generation Bio Co website?

https://generationbio.com

Is Generation Bio Co in the S&P 500?

No, Generation Bio Co is not included in the S&P 500 index

Is Generation Bio Co in the NASDAQ 100?

No, Generation Bio Co is not included in the NASDAQ 100 index

Is Generation Bio Co in the Dow Jones?

No, Generation Bio Co is not included in the Dow Jones index

When was Generation Bio Co the previous earnings report?

No data

When does Generation Bio Co earnings report?

The next expected earnings date for Generation Bio Co is 08 November 2024